Vancomycin Therapeutic Drug Monitoring (AUC-guided)

Pharmacokinetics / TDM

📈 Vancomycin Therapeutic Drug Monitoring (AUC-guided)

ASHP/IDSA/SIDP 2020 consensus guidelines moved vancomycin monitoring from trough-only to AUC/MIC-guided dosing. This reference summarizes the clinical rationale, target AUC, monitoring approach, and common pitfalls.

📋 Printable Quick Card →

Why AUC-Guided Monitoring?

Trough-only monitoring correlates poorly with efficacy and was associated with higher rates of nephrotoxicity, particularly when troughs were pushed to 15–20 mg/L to achieve target exposure. The 2020 guidelines replaced trough-only targets with AUC/MIC targets because:

AUC/MIC is the pharmacodynamic index that best predicts clinical efficacy for MRSA
High troughs (15–20 mg/L) to achieve AUC target are not necessary and increase toxicity risk
Bayesian software allows accurate AUC estimation from 1–2 blood draws without needing true steady-state

Target AUC and MIC

Parameter	Target	Notes
AUC₂₄/MIC	400–600 mg·h/L	For serious MRSA infections (bacteremia, pneumonia, osteomyelitis, meningitis)
Assumed MIC	1 mg/L	If susceptibility testing not performed; use actual MIC if available
Target AUC₂₄	400–600 mg·h/L	When MIC = 1 mg/L (most common scenario)
Trough (informational only)	10–20 mg/L	Not used as primary target; troughs 10–15 mg/L typically adequate when AUC is on target

Monitoring Approach

Method	When to Use	Draw Times
Bayesian AUC estimation (preferred)	All patients; most accurate	Flexible: one peak + one trough after ≥2 doses, OR two troughs at different time points
Two-level AUC estimation	When Bayesian software unavailable	Peak 1–2h post-infusion, trough within 30 min before next dose. Both from same dosing interval at steady state.
Trough-only (legacy)	Not recommended per 2020 guidelines	—

🔧 Vancomycin dosing depends on renal function. Use the CrCl / eGFR calculator to estimate creatinine clearance.

Nephrotoxicity Definition & Monitoring

ASHP/IDSA/SIDP 2020 definition of VAN-AKI: An increase in SCr ≥0.5 mg/dL or ≥50% from baseline on ≥2 consecutive measurements ≥24 h apart, in the absence of an alternative explanation.

Monitor SCr at baseline and every 48–72h during therapy (daily in ICU or hemodynamically unstable patients)
Hold or reduce dose if SCr rises significantly; reassess for alternative causes (NSAIDs, contrast, hypotension)
AUC-guided dosing reduces VAN-AKI incidence vs. trough-only, estimated NNT approximately 11 to prevent one case of AKI

PharmD Clinical Pearls

💡 Vancomycin is NOT appropriate empiric therapy for MRSA pneumonia when the isolate MIC is ≥2 mg/L. Consider alternative agents (ceftaroline, linezolid, daptomycin, though daptomycin is inactivated by surfactant and should not be used for pneumonia).

💡 In patients on CRRT, vancomycin clearance is highly variable and depends on filter type, flow rates, and membrane. AUC monitoring is especially important; redosing intervals of q24–48h are common starting points.

💡 Older observational data linked concomitant piperacillin-tazobactam to higher rates of rising creatinine with vancomycin, but the 2023 ACORN randomized trial found no difference in AKI versus cefepime, and some of the earlier signal likely reflects pseudotoxicity (pip-tazo inhibits tubular creatinine secretion) rather than true injury. The association remains debated; it's reasonable to consider cefepime or meropenem in patients at high nephrotoxicity risk, but pip-tazo need not be reflexively avoided.

💡 Vancomycin is poorly absorbed orally. Oral dosing is only indicated for Clostridioides difficile colitis, not systemic infections.

🎓

Reviewed by a licensed pharmacist

Reference content reviewed for clinical accuracy. This is not a substitute for institutional protocols or professional judgment.

← Back to Clinical Reference · Literature Archive →